The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates

Vaccine

Volumn 17, Issue 18, 1999, Pages 2311-2319

  Gómez, Carmen E ^a   Navea, Leonor ^b   Lobaina, Leonor ^b   Dubed, Marta ^b   Expósito, Néstor ^a   Soto, Alejandro ^a   Duarte, Carlos A ^a  

^a Division de Vacunas   (Cuba)

^b Laboratorio de Investigaciones del SIDA   (Cuba)

Author keywords

HIV 1; Macaques; Montanide ISA 720; V3 loop; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CONSENSUS SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HIV-1; IMMUNODOMINANT EPITOPES; MACACA RADIATA; MANNITOL; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; OILS; OLEIC ACIDS; PEPTIDES;

EID: 18344406913     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00358-2     Document Type: Article

References (24)

1. Esparza J., Heyward W.L., Osmanov S. HIV vaccine development: from basic research to human trials. AIDS. 10 (Suppl A):1996;S123-S132.
2. Emini E., Nara P.O., Schleif W.A., Lewis J.A., Davide J.P., Lee D.R., Kessler J., Conley S., Matsusshita S., Putney S., Gerety R., Eichberg J. Antibody mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol. 64(8):1990;3674-3678.
3. Girard M., Kieny M.P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E., Ronco J., Kaczoreck M., Gomard E., Gluckman J.C., Fultz P. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA. 88:1991;542-546.
4. Emini E., Schleif W.A., Numberg J.H., Conley A.J., Eda Y., Tokiyoshi S., Putney S.D., Matsushita S., Cobb K.E., Jett C.M., Eichberg J.W., Murthy K.K. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain specific monoclonal antibody. Nature. 355:1992;728-730.
5. Safrit J., Fung M., Andrews C.A., Braun D.G., Sun W., Chang T., Koup R. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS. 7:1993;15-21.
6. Silva R, Selman M, Guillén G, Herrera L, Fernández JR et al. Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations. European Patent Application 0 474 313 A2, 1992.
7. Duarte C.A., Montero M., Seralena A., Valdés R., Jiménez V., Benítez J., Narciandi E., Madrazo J., Padrón G., Sánchez G., Gilljan G., Persson K., Domínguez M., Ojeda S., Caballero A., Wahren B., Menéndez A. Multi-epitope polypeptide (MEP) containing epitopes of HIV-1 envelope induces neutralizing monoclonal antibodies against the V3 loop. AIDS Res Hum Retroviruses. 10(3):1994;235-243.
8. Montero M., Menéndez A., Domínguez M.C., Navea L., Vilarubia O.L., Quintana D., Izquierdo M., Jiménez V., Reyes O., Lobaina L., Noa E., Duarte C.A. Broadly reactive antibodies against a gp120 V3-loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1). Vaccine. 15(11):1997;1200-1208.
9. Menéndez A, Montero M, Quintana D, Gómez C, Navea L et al. V3 multi-epitope polypeptides: the number of V3 regions affects the exposition of epitopes and immunogenicity. XI International Conference on AIDS, Vancouver 1996. Abstract Book, 1: 212, Tu-A.2104.
10. Herrera A, Vázquez D, Quintana D, Navea LN, Lobaina L, Nápoles A, Duarte C. Selection of an appropriate adjuvant for vaccination with HIV-1 derived multi-epitope polypeptides (MEPs). XII International Conference on AIDS, Geneva 1998. Abstract Book: 637, Abstract 33224.
11. Houghten R.A. General method for the rapid synthesis of large number of peptides. Specificity of antigen antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA. 82:1985;5131.
12. Gómez C.E., López-Campistrous A.E., Duarte C.A. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti-V3 antibodies in HIV-1+ human sera. J Virol Methods. 71:1998;7-16.
13. Ross A.M., Clifford S.H., Colin L.J. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunological Methods. 106:1988;191-194.
14. Akerblom L., Hinkula J., Broliden P., Mäkitalo H., Fridbrger T., Rosen J., Eriksson M.V., Morein B., Wahren B. Neutralizing monoclonal antibodies to HIV-1 gp120. AIDS. 4:1990;953-960.
15. Scalzo A.A., Elliot S.L., Cox J., Gardner J., Moss D.J., Suhrbier A. Induction of protective cytotoxic T cells to murine cytomegalovirus by usuing a nonapeptide and a human-compatible adjuvant (montanide ISA 720). J Virol. 69(2):1995;1306-1309.
16. Pye D., Vandenberg K.L., Dyer S.L., Irving D.O., Goss N.H., Woodrow G.C., Saul A., Alving C.R., Richards R., Ballou W.R., Wu M.J., Skoff K., Anders R. Selection of and adjuvant for vaccination with the malaria antigen, MSA2. Vaccine. 15(9):1997;1017-1023.
17. Kirkley J.E., Goldstein A.L., Naylor P.H. Adjuvant properties of montanide CSA720 with a recombinant HIV P17 gag protein and synthetic peptide antigens. Scand J Immunol. 43:1996;431-438.
18. Vahlne A., Horal P., Eriksson K., Jeansson S., Rymo L., Hedstrom K.G., Czerkinsky C., Holmgren J., Svennerholm B. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition associated with cross-neutralizing antibodies and T cell recognition. Proc Natl Acad Sci USA. 88:1991;10744-10748.
19. Newman M.J., Wu J.Y., Coughlin R.T., Murphy C.I., Seals J.R., Wyand M.S., Kensil C.R. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates. AIDS Res Hum Retroviruses. 8(8):1992;1413-1418.
20. Goudsmit J., Boucher A.B., Meloen R.H., Epstein L.G., Smit L., Hoeket al. Immunodominant B-cell epitopes of HIV-1 envelope recognized by infected and immunized host. AIDS. 2:1988;157-164.
21. Wilson I, Stanfield R, Ghiara J, Stura E, Satterthwait A, Profy A. Structural basis for recognition of HIV-1 by two broadly neutralizing monoclonal antibodies. IVth Int. Conf. AIDS, Berlin, 1993, WS-A21-1, Abstract book 1: 37.
22. Ghiara J., Stura E., Stanfield R., Profy A., Wilson I. Crystal structure of the principal neutralization site of HIV-1. Science. 264:1994;82-85.
23. Edward N., Janoff N., David H., Phillip B., Sharon M. Humoral recall responses in HIV infection levels, specificity and affinity of antigen-specific IgG. J Immunol. 147(2):1991;130-135.
24. Vancott T.C., Bethke F.R., Polonis V.R., Gorny M., Zolla-Pazner S., Redfield R.R., Birx D.L. Dissociation rate of antibody gp120 binding interactions is predictive of V3 mediated neutralization of HIV-1. J Immunol. 153(1):1994;449-459.